Pentagon opens $billions in grants to biotech firms—no purchase guarantee required
H.R. 5187 — To establish in the Department of Defense a program to support the expansion of domestic bioindustrial manufacturing capacity. · Filed by Ro Khanna (D-CA) · 2 cosponsors · Introduced Sep 8, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill authorizes the Department of Defense to create a competitive grant program awarding federal funds to private companies that build, upgrade, or retool factories to manufacture biological products (chemicals, materials, and other goods made using living systems) that the military needs. The program runs for 10 years, with annual reporting to Congress on which companies received awards, how much money they got, and what they're producing.
Why we flagged it
The bill's operative mechanism is a federal grant program channeling DoD funds to private biomanufacturing companies. While framed as national security and supply-chain resilience, it is functionally a targeted subsidy to an emerging industrial sector with no public-interest mandate (price controls, civilian access, or competitive procurement requirements).
What the text implies
- No requirement that DoD actually purchase products from award recipients—grants fund facility buildout but do not guarantee military contracts, creating a one-way transfer of public funds to private industry.
- Award criteria (B) references 'next generation of warfighters' but does not define what products are required or how civilian dual-use applications factor into selection, leaving military demand undefined.
- Geographic distribution criterion (D) may fragment manufacturing capacity across multiple sites for political reasons rather than economic efficiency, raising cost per unit.
- Sunset clause allows indefinite extension if the President deems continuation necessary for 'national economic and national security needs'—a broad standard that could lock in permanent subsidies.
- No price-control, affordability, or public-access provisions; products developed with federal funds may be sold exclusively to DoD or at commercial rates, capturing public investment as private profit.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill funds domestic manufacturing capacity and supply-chain resilience, which serve national security and potentially create jobs. However, it is a direct federal subsidy to private companies with no guarantee of public benefit, competitive pricing, or that the products will be affordable or available to civilians—the military's needs drive the program, and DoD has broad discretion over awards with minimal transparency requirements.
Who stands to gain
- private biomanufacturing companies
- biotech and synthetic biology firms
- contract manufacturers in chemical and materials sectors
Named in the bill
Department of Defense, Secretary of Defense, House Committee on Armed Services, private bioindustrial entities, U.S. biomanufacturing sector
Where it stands
2 cosponsors: 2 Democrats.
- Sep 8, 2025 — Introduced · Congress.gov: “Introduced in House”
- Sep 8, 2025 — Referred to House Committee on Armed Services · Congress.gov: “Referred to the House Committee on Armed Services”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
2 lobbying clients named this bill on 2 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $20,000 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 41% of bills with at least one filing.
Ro Khanna, the sponsor, reported $0 in PAC receipts in the 2026 cycle.
- Agios Pharmaceuticals — $10,000 on 1 filing
- Beam Therapeutics — $10,000 on 1 filing
Lobbying Disclosure Act filings through Jul 16, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (7,911 characters) on Jun 3, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 16, 2026 · page rendered 2026-10-20.
“Pentagon opens $billions in grants to biotech firms—no purchase guarantee required” QuorumCivic. https://share.quorumcivic.app/bill/119/hr5187 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.